[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1124093T1 - Ανοσογονικες συνθεσεις bordetella bronchiseptica - Google Patents

Ανοσογονικες συνθεσεις bordetella bronchiseptica

Info

Publication number
CY1124093T1
CY1124093T1 CY20211100386T CY211100386T CY1124093T1 CY 1124093 T1 CY1124093 T1 CY 1124093T1 CY 20211100386 T CY20211100386 T CY 20211100386T CY 211100386 T CY211100386 T CY 211100386T CY 1124093 T1 CY1124093 T1 CY 1124093T1
Authority
CY
Cyprus
Prior art keywords
bordetella bronchiseptica
immune compositions
compositions
immune
bronchiseptica
Prior art date
Application number
CY20211100386T
Other languages
English (en)
Inventor
Omar Yousif Abdelmagid
Joseph Michael BRICKER
Shelly Lynn Shields
Jeffrey E. Galvin
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1124093T1 publication Critical patent/CY1124093T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στο παρόν παρέχονται συνθέσεις, συνδυασμοί και μέθοδοι που περιλαμβάνουν Bordetella bronchiseptica και απομονωμένη περτακτίνη, οι οποίες είναι αποτελεσματικές στη θεραπεία ή πρόληψη αναπνευστικών λοιμώξεων, όπως βήχας του κυνοτροφείου, σε ζώα.
CY20211100386T 2011-02-04 2021-05-06 Ανοσογονικες συνθεσεις bordetella bronchiseptica CY1124093T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439597P 2011-02-04 2011-02-04
PCT/IB2012/050512 WO2012104821A1 (en) 2011-02-04 2012-02-03 Immunogenic bordetella bronchiseptica compositions

Publications (1)

Publication Number Publication Date
CY1124093T1 true CY1124093T1 (el) 2022-05-27

Family

ID=45755432

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100386T CY1124093T1 (el) 2011-02-04 2021-05-06 Ανοσογονικες συνθεσεις bordetella bronchiseptica

Country Status (27)

Country Link
US (1) US20130302369A1 (el)
EP (2) EP2670432B1 (el)
JP (1) JP5833145B2 (el)
KR (1) KR101647180B1 (el)
CN (2) CN103561763A (el)
AU (2) AU2012213035A1 (el)
BR (1) BR112013019675B8 (el)
CA (1) CA2826060C (el)
CL (1) CL2013002219A1 (el)
CO (1) CO6791568A2 (el)
CY (1) CY1124093T1 (el)
DK (1) DK2670432T3 (el)
ES (1) ES2869175T3 (el)
HK (1) HK1245676A1 (el)
HR (1) HRP20210575T1 (el)
HU (1) HUE055669T2 (el)
LT (1) LT2670432T (el)
MX (1) MX347177B (el)
PL (1) PL2670432T3 (el)
PT (1) PT2670432T (el)
RS (1) RS61723B1 (el)
RU (1) RU2554480C2 (el)
SI (1) SI2670432T1 (el)
SM (1) SMT202100233T1 (el)
UA (2) UA110504C2 (el)
WO (1) WO2012104821A1 (el)
ZA (1) ZA201306615B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
ES2748205T3 (es) * 2012-05-31 2020-03-13 Zoetis Services Llc Vacunación con coronavirus respiratorio canino para protección contra infecciones por B. Bronchiseptica
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
BR112016012127A2 (pt) * 2013-11-26 2017-09-26 Zoetis Services Llc composições para a indução da resposta imunológica
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571618A1 (fr) 1984-10-12 1986-04-18 Virbac Ctre Rech Biolog Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
PT1015026E (pt) * 1996-05-31 2006-08-31 Nat Univ Ireland Maynooth Il-12 como adjuvante para vacinas contra bordetella pertussis
RO120819B1 (ro) * 1996-07-02 2006-08-30 Connaught Laboratories Limited Vaccinuri dtp multivalente
EP1284993B1 (en) * 2000-05-25 2008-04-23 Institut Pasteur Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella paraperussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
WO2004067031A1 (en) 2003-01-29 2004-08-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP1667712B1 (en) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
EP1871410A2 (en) * 2005-04-07 2008-01-02 Pharmacia & Upjohn Company LLC Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
BRPI0616328A2 (pt) * 2005-10-07 2011-06-14 Pfizer Prod Inc vacinas e mÉtodos para tratar influenza canino
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2007252296A1 (en) * 2006-05-19 2007-11-29 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions

Also Published As

Publication number Publication date
UA110504C2 (ru) 2016-01-12
CN103561763A (zh) 2014-02-05
EP2670432B1 (en) 2021-03-17
HUE055669T2 (hu) 2021-12-28
KR20130118975A (ko) 2013-10-30
CO6791568A2 (es) 2013-11-14
CN107296955A (zh) 2017-10-27
NZ613759A (en) 2015-09-25
RU2013136151A (ru) 2015-03-10
AU2017203244B2 (en) 2019-05-09
HRP20210575T1 (hr) 2021-05-28
AU2012213035A1 (en) 2013-08-15
BR112013019675A2 (pt) 2017-01-31
PT2670432T (pt) 2021-05-04
EP3858381A1 (en) 2021-08-04
CA2826060A1 (en) 2012-08-09
PL2670432T3 (pl) 2021-10-11
JP2014504635A (ja) 2014-02-24
US20130302369A1 (en) 2013-11-14
JP5833145B2 (ja) 2015-12-16
HK1245676A1 (zh) 2018-08-31
CL2013002219A1 (es) 2014-01-31
MX2013009012A (es) 2013-12-06
SMT202100233T1 (it) 2021-05-07
MX347177B (es) 2017-04-17
ZA201306615B (en) 2015-04-29
CN107296955B (zh) 2021-11-23
BR112013019675B1 (pt) 2021-06-22
RS61723B1 (sr) 2021-05-31
DK2670432T3 (da) 2021-04-19
WO2012104821A1 (en) 2012-08-09
EP2670432A1 (en) 2013-12-11
SI2670432T1 (sl) 2021-08-31
ES2869175T3 (es) 2021-10-25
AU2017203244A1 (en) 2017-06-08
BR112013019675B8 (pt) 2022-11-22
KR101647180B1 (ko) 2016-08-09
RU2554480C2 (ru) 2015-06-27
UA110505C2 (ru) 2016-01-12
CA2826060C (en) 2019-06-18
LT2670432T (lt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1124093T1 (el) Ανοσογονικες συνθεσεις bordetella bronchiseptica
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
ZA202305280B (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CY1119165T1 (el) Παραγωγα βενζιμιδαζολονης ως αναστολεις βρωμοπεδιου
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1116383T1 (el) Αντιβακτηριακες ενωσεις
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
CY1115708T1 (el) Τοπικες συνθεσεις για τη διατηρηση ή την ανακτηση της ακεραιοτητας των βλεννογονων
CR20170455A (es) Nuevos compuestos bicíclicos
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1120355T1 (el) Αναστολεις toy iap
MX2018003294A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
EA201691412A1 (ru) Гидроксиформамидные производные и их применение